Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study

Trial Profile

Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2018

At a glance

  • Drugs MRG-110 (Primary)
  • Indications Heart failure; Ischaemia
  • Focus Adverse reactions; First in man
  • Sponsors Servier
  • Most Recent Events

    • 07 Nov 2018 According to a miRagen Therapeutics media release, the company expects to report the data from this trial in 2019.
    • 20 Sep 2018 Planned End Date changed from 13 Jan 2020 to 24 Mar 2020.
    • 20 Sep 2018 Planned primary completion date changed from 14 Jan 2019 to 25 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top